New Delhi: Fresenius Medical Care nih a chuahpimi ruahnak cheuhnak lehnak ah, Central Drugs Standard Control Organization (CDSCO) i Specialty Expert Committee (SEC) nih company cu cohlannak caah a ruang kha calcium chloride dihydrate i phase III sii lei hneksaknak data le hnatlaknak hnu zohfelnak data he ram dang ruahnak cheuhnak caah pek dingin ruahnak a pek.
Company nih a hlan ah 100 mmol/L a tlawmmi calcium chloride dihydrate cawhnuk sernak le zuarnak caah soknak a rak tuah cang, mah cu “calcium thlennak thlopnak ah pehzulh tein kal thlennak thlopnak (CRRT), pehzulh tein tthatnak a tlawmmi (nifatin) dialysis (CLED) le thlopbulnak plasma thlennak (TPE) caah hmanmi a si. upa le ngakchia caah aa tlakmi” tiah a ti i phase III le phase IV sii lei hneksaknak in chuahnak a ruang kha a chim.
Committee nih thilri cu Europe ram Portugal, United Kingdom, Brazil, Switzerland, France le Denmark tibantuk ah cohlan a si cang tiah an hmuh.
Calcium chloride dihydrate timi compound cu CaCl2 2H2O a si, cucu calcium chloride pakhat ah ti molecule pahnih aa telmi calcium chloride a si. Ti ah a cawh khomi le ti a tlawmmi, thli chungin ti a lak khawhmi, a senmi lungvar a si.
Calcium chloride dihydrate cu methanol ah a cawh tikah chitin cawhnak caah cawhmi thilri ah hman khawhmi thilri pakhat a si. Chitin i a tlongmi sining hrawhnak ah a biapi tukmi rian a ttuan i chemistry lei ah hmannak phunphun a ngei.
May 20, 2025 ah tuahmi SEC Nephrology meeting ah, panel nih 100 mmol/L calcium chloride dihydrate infusion solution sernak le zuarnak hnatlaknak tuah ding in ruahnak cheuhnak an zohfel i, cu cu “calcium thlennak thlopnak ah pehzulh tein kal thlennak thlopnak (CRRT), pehzulh tein tthatnak a tlawmmi (DDDS) thlopnak ah hman ding a si plasma thlennak (TPE) cu citrate anticoagulation he. Thilri cu upa le ngakchia caah langhter a si” i phase III le IV sii lei hneksaknak in luatnak caah a ruang a pek.
A tlingmi biaruahnak hnu ah, committee nih cohlannak hrampi, cun phase III sii hneksaknak data le sii a cohlang cangmi ram hna in zuar hnu zohfelnak data hna kha committee sinah ruahnak cheuhnak caah pek ding in ruahnak an cheuh.
Cun rel chih: CDSCO phu nih Sanofi's Myozyme caah min cazin thar an cohlan, phunglam zohfelnak an hal
Dr. Divya Kolin cu PharmD a dihmi a si i sii lei le sizung lei hmuhtonnak tampi a ngei i zawtnak thlopnak le thlopnak thiamnak ttha a ngei. Mysore Medical College le Research Institute ah oncology lei zung ah oncology siibawi rian zong a ttuan cang. A tu ah sii lei hlathlainak le sii lei data zohkhenhnak ah a rian a ttuan lio a si. Amah cu January 2022 thawk in Medical Dialogue he rian a ttuan.
       Dr Kamal Kant Kohli, MBBS, MD, CP, is a thoracic specialist with over 30 years of experience and specializes in clinical writing. He joins Medical Dialogues as the Editor-in-Chief of Medical News. Apart from writing articles, as the Editor, he is responsible for proofreading and reviewing all medical content published in Medical Dialogues, including content from journals, research papers, medical conferences, guidelines, etc. Email: drkohli@medicaldialogues.in Contact: 011-43720751
ABYSS hlathlainak nih lungthin zawtnak hnu ah beta-blockers ngolternak nih thikai, lungthin riantuan ning le lungthin lei ah a ttha lomi thil a chuahter ti a hmuh: …